Teva hopes Sanofi collaboration will lead to blockbuster IBD drug
Send a link to a friend
[October 04, 2023]
By Steven Scheer
JERUSALEM (Reuters) -Teva Pharmaceutical Industries will collaborate
with French drugmaker Sanofi to develop a treatment for inflammatory
bowel disease it hopes will become a blockbuster drug.
Sanofi, a leader in immunology, will invest $1.5 billion in the
development of Teva's anti-TL1A drug, the companies said on Wednesday.
The drug is still in phase 2 trials, with interim results not expected
until the second half of 2024,
Phase 3 trials are expected to begin in 2025 and Teva chief executive
Richard Francis said the best case scenario for the commercial launch of
the drug -- which will target both Crohn's disease and ulcerative
colitis -- would be around 2028.
"The fact that they've done their due diligence on our anti-TL1A asset
... and to put up $1.5 billion, as well as allow Teva to retain 50% of
the worldwide economics once it's launched, I think shows that they
believe in the asset," Francis told Reuters.
Paul Hudson, Sanofi's CEO, said anti-TL1As are a promising class of
therapies and that Teva's version could emerge as a best-in-class option
for people living with serious gastrointestinal diseases.
"This collaboration strengthens our commitment to advancing innovative
treatment options for inflammatory conditions with a high unmet need and
bolsters our goal to be an industry leader in immunology," Hudson said.
Teva shares were down 3% in midday trade in Tel Aviv, with the broader
market also lower, while Sanofi's shares were up 1% in Paris.
Israel-based Teva, the world's largest generics drugmaker, has struggled
to recover from the loss of exclusivity to its multiple sclerosis drug
Copaxone, and to cut $35 billion of debt as it fought a spate of
lawsuits alleging it helped fuel the U.S. opioid epidemic.
But Teva has started to show signs of recovery and is betting a trio of
the group's branded drugs - Austedo, migraine product Ajovy and
schizophrenia drug Uzedy - will help the company bounce back. Teva also
has a number of biosimilars in its pipeline.
[to top of second column]
|
The logo of Teva Pharmaceutical Industries is seen in Tel Aviv,
Israel February 19, 2019. REUTERS/Amir Cohen/file photo
"We want to get Teva back to
growth," Francis said, noting it raised its 2023 revenue outlook in
August. "To continue that growth, we've got to drive our products in
the market forward."
LONG-TERM GROWTH
Francis estimated the IBD market was worth nearly $30 billion and
said many patients do not respond to current treatments.
With TL1A viewed as a long-term growth driver, Francis said it
needed a "world class partner" such as Sanofi to help it develop and
market the drug.
Under the terms of the deal, Teva will receive an upfront payment of
$500 million in cash once the transaction closes, which is expected
by the end of 2023, and up to $1 billion in development and launch
milestones.
Both companies will equally share the development costs globally and
net profits and losses in major markets, with other markets subject
to a royalty arrangement. Sanofi will lead the development of the
phase 3 clinical trials, Teva said.
Teva, which will report third-quarter results on Nov. 8, will lead
commercialization of the product in Europe, Israel and specified
other countries, and Sanofi will lead commercialization in North
America, Japan, other parts of Asia and the rest of the world.
($1 = 0.9555 euros)
(Reporting by Steven Scheer; Editing by Sharon Singleton, Alex
Richardson and Christina Fincher)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|